Joseph A. Sliman Net Worth

What's Joseph Sliman's mailing address?

Joseph's mailing address filed with the SEC is C/O SYNTHETIC BIOLOGICS, INC.,, 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850.

Insiders trading at Theriva Biologics Inc

Over the last 12 years, insiders at Theriva Biologics Inc have traded over $8,016,723 worth of Theriva Biologics Inc stock and bought 6,682,900 units worth $10,572,593 . The most active insiders traders include Randal Jintrexon Corp Kirk, Steve H Kanzer et Scott Tarriff. On average, Theriva Biologics Inc executives and independent directors trade stock every 223 days with the average trade being worth of $899,000. The most recent stock trade was executed by Steven A Shallcross on 10 May 2021, trading 50,000 units of SYN stock currently worth $24,500.

What does Theriva Biologics Inc do?

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Theriva Biologics Inc executives and stock owners

Theriva Biologics Inc executives and other stock owners filed with the SEC include:

• Steven Shallcross,
  Chief Executive Officer, Chief Financial Officer, Director
• Steven A. Shallcross CPA,
  CEO, CFO, Treasurer, Corp. Sec. & Director
• Jeffrey Kraws,
  Non-Executive Independent Chairman of the Board
• John Monahan,
  Director
• Jeffrey Wolf,
  Independent Director
• Dr. Frank Tufaro Ph.D.,
  Chief Operating Officer
• Lara M. Guzman,
  Sr. Director of Project Operations
• Dr. Michael Kaleko,
  Sr. VP of R&D
• Dr. Vince Wacher,
  Head of Product and Corp. Devel.
• Vincent I. Perrone,
  Director of Corp. Communication
• Jeffrey Scott Riley,
  CEO and President
• Randal Jintrexon Corp Kirk,
  
• Joseph A. Sliman,
  Chief Medical Officer
• Steve H Kanzer,
  10% owner
• Charles Evan Ballantyne,
  Chief Financial Officer
• Scott Tarriff,